微电生理(688351) - 2024 Q2 - 季度业绩预告

Financial Performance Expectations - The company expects net profit attributable to shareholders to be between RMB 15 million and RMB 20 million, representing a year-on-year increase of 595.92% to 827.89%[3]. - The estimated operating revenue for the first half of 2024 is projected to be between RMB 195 million and RMB 210 million, an increase of RMB 52.88 million to RMB 67.88 million, or 37.21% to 47.76% year-on-year[11]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be between RMB 800,000 and RMB 1.2 million, an increase of RMB 1,316.59 million to RMB 1,356.59 million compared to the same period last year[12]. - The earnings per share for the period is projected to be RMB 0.0046[14]. - The company reported a total profit of RMB 2.1554 million, with a net profit attributable to shareholders of RMB 2.1554 million, while the net profit after deducting non-recurring gains and losses was RMB -12.3659 million[5]. - The company emphasizes that the performance forecast has not been audited by registered accountants, and the final financial data will be disclosed in the official 2024 semi-annual report[4][8]. - The company has indicated that there are no significant uncertainties affecting the accuracy of this performance forecast[7]. Market Strategy and Product Focus - The company has focused on the cardiac electrophysiology field and is advancing its global strategy, particularly in the atrial fibrillation market[6]. - The sales proportion of high-value consumables such as TrueForce® pressure monitoring RF ablation catheter and IceMagic® cryoablation series products has significantly increased, enhancing the company's competitiveness in the electrophysiology market[6]. - The company is actively promoting the market access and promotion of TrueForce® in European countries, aiming to increase brand influence and penetration in overseas markets[6].